The unvetted and highly controversial measure could pass within just weeks of being proposed and outside of the standard ...
We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to ...
Stocks of anti-obesity drugmakers Eli Lilly , Novo Nordisk , and Amgen have gotten hit as the market frets over what a Robert F. Kennedy Jr.-run Department of Health and Human Ser ...
LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...
1d
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...
We recently compiled a list of the Jim Cramer on Nvidia Plus Other Stocks. In this article, we are going to take a look at ...
The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income ...
Uptake of continuous glucose monitoring (CGM) was relatively low among vulnerable diabetes patients in the largest national ...
Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.
French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income ...
There's no cure for this disease, but now there is some hope for people and their families who are battling the illness in ...
The 340B program has received its share of criticisms, largely due to the lack of transparency into covered entities who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback